$-0.19 EPS Expected for CareDx Inc (CDNA)

October 15, 2017 - By Marie Mckinney

 $ 0.19 EPS Expected for CareDx Inc (CDNA)
Investors sentiment decreased to 0.73 in 2017 Q2. Its down 0.49, from 1.22 in 2017Q1. It fall, as 6 investors sold CareDx Inc shares while 5 reduced holdings. 2 funds opened positions while 6 raised stakes. 6.38 million shares or 18.44% less from 7.82 million shares in 2017Q1 were reported.
Paragon Associate Paragon Associate Ii Joint Venture reported 1.61% in CareDx Inc (NASDAQ:CDNA). Blackrock Incorporated has invested 0% of its portfolio in CareDx Inc (NASDAQ:CDNA). Northern has invested 0% in CareDx Inc (NASDAQ:CDNA). Tower Cap (Trc) accumulated 0% or 3,911 shares. Vanguard Gru Incorporated holds 0% or 248,084 shares. Barclays Pcl reported 41 shares. Morgan Stanley has invested 0% in CareDx Inc (NASDAQ:CDNA). Moreover, Thompson Davis has 0.01% invested in CareDx Inc (NASDAQ:CDNA). New York-based Teton has invested 0% in CareDx Inc (NASDAQ:CDNA). Geode Capital Mngmt holds 0% of its portfolio in CareDx Inc (NASDAQ:CDNA) for 43,139 shares. Panagora Asset, a Massachusetts-based fund reported 52,054 shares. Tpg Gru Holdings (Sbs) Advsrs stated it has 174,378 shares or 0% of all its holdings. Goldman Sachs Grp Inc invested 0% in CareDx Inc (NASDAQ:CDNA). California Public Employees Retirement Sys accumulated 175,000 shares. Moreover, Gagnon Limited Liability Company has 0.91% invested in CareDx Inc (NASDAQ:CDNA) for 954,272 shares.

Since May 23, 2017, it had 2 insider buys, and 0 selling transactions for $14,548 activity.

Analysts expect CareDx Inc (NASDAQ:CDNA) to report $-0.19 EPS on November, 8.They anticipate $0.02 EPS change or 11.76 % from last quarter’s $-0.17 EPS. After having $-0.19 EPS previously, CareDx Inc’s analysts see 0.00 % EPS growth. The stock decreased 5.80% or $0.34 on October 13, reaching $5.52. About 353,999 shares traded. CareDx Inc (NASDAQ:CDNA) has declined 74.10% since October 16, 2016 and is downtrending. It has underperformed by 90.80% the S&P500.

CareDx Inc (NASDAQ:CDNA) Ratings Coverage

Among 4 analysts covering CareDx (NASDAQ:CDNA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CareDx had 7 analyst reports since September 25, 2015 according to SRatingsIntel. Raymond James upgraded the shares of CDNA in report on Wednesday, September 27 to “Outperform” rating. Raymond James downgraded the stock to “Market Perform” rating in Monday, September 28 report. The firm has “Buy” rating given on Friday, September 25 by Craig Hallum. The rating was maintained by Craig Hallum on Monday, October 9 with “Buy”. The stock of CareDx Inc (NASDAQ:CDNA) earned “Buy” rating by Piper Jaffray on Sunday, September 24. The company was maintained on Tuesday, June 14 by Mizuho.

CareDx, Inc. is a molecular diagnostics company. The company has market cap of $142.21 million. The Firm is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. It currently has negative earnings. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test , is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

More important recent CareDx Inc (NASDAQ:CDNA) news were published by: Globenewswire.com which released: “AlloMap’s Medicare reimbursement to increase in 2018” on September 22, 2017, also Globenewswire.com published article titled: “CareDx Announces Closing of Public Offering of Common Stock”, Prweb.com published: “CareDx Announces Pricing of Upsized Public Offering of Common Stock” on October 05, 2017. More interesting news about CareDx Inc (NASDAQ:CDNA) was released by: Streetinsider.com and their article: “UPDATE: CareDx, Inc (CDNA) PT Raised to $7 at Piper Jaffray” with publication date: September 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com